Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.

Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB.

Clin Pharmacol Ther. 2002 Jul;72(1):1-9.

2.

Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers.

Fontana RJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS, Knize MG, Greenberg A, Watkins PB.

Gastroenterology. 1999 Jul;117(1):89-98.

PMID:
10381914
3.

Molecular and physical mechanisms of first-pass extraction.

Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA.

Drug Metab Dispos. 1999 Feb;27(2):161-6. Review.

PMID:
9929497
4.

Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical.

Lown KS, Ghosh M, Watkins PB.

Drug Metab Dispos. 1998 Feb;26(2):185-7.

PMID:
9456307
5.

Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins.

Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB.

Drug Metab Dispos. 1997 Nov;25(11):1228-33.

PMID:
9351897
6.

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB.

Clin Pharmacol Ther. 1997 Sep;62(3):248-60.

7.

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB.

J Clin Invest. 1997 May 15;99(10):2545-53.

8.

Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.

Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB.

Mol Pharmacol. 1997 May;51(5):741-54.

PMID:
9145912
9.

Selective expression of CYP3A5 and not CYP3A4 in human blood.

Janardan SK, Lown KS, Schmiedlin-Ren P, Thummel KE, Watkins PB.

Pharmacogenetics. 1996 Oct;6(5):379-85.

PMID:
8946469
10.

Update of the Adult and Pediatric Liver Transplant Program at the University of Michigan.

Turcotte JG, Magee JC, Bromberg JS, Campbell DA, Dickinson CJ, Fontana RJ, Henley KS, Hillemeier AC, Lok AS, Lown KS, Olson AD, Punch JD, Su GL, Merion RM.

Clin Transpl. 1996:203-16.

PMID:
9286569
11.

The erythromycin breath test predicts the clearance of midazolam.

Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB.

Clin Pharmacol Ther. 1995 Jan;57(1):16-24.

12.

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB.

Drug Metab Dispos. 1994 Nov-Dec;22(6):947-55. Erratum in: Drug Metab Dispos 1995 Mar;23(3):followi.

PMID:
7895614
13.

CYP3A gene expression in human gut epithelium.

Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB.

Pharmacogenetics. 1994 Oct;4(5):247-59.

PMID:
7894497
14.

P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients.

Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, Watkins PB.

Clin Pharmacol Ther. 1994 Sep;56(3):253-60.

15.

Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients.

Turgeon DK, Leichtman AB, Blake DS, Schmouder RL, Lown KS, Annesley TM, Watkins PB.

Transplantation. 1994 Jun 27;57(12):1736-41.

PMID:
8016878
16.

The self-sustained sequence replication amplification system--move over, PCR.

Lown KS.

Hepatology. 1993 Feb;17(2):344-6. No abstract available.

17.

Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.

Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, Fishman K, Guzelian PS, Voorhees JJ.

Clin Pharmacol Ther. 1992 Sep;52(3):265-73.

18.

Predicting drug interactions using cultured human hepatocytes.

Lown KS, Watkins PB.

Hepatology. 1991 Aug;14(2):396-8. No abstract available.

Supplemental Content

Support Center